129 related articles for article (PubMed ID: 33782811)
1. Low RAI2 expression is a marker of poor prognosis in breast cancer.
Nishikawa S; Uemoto Y; Kim TS; Hisada T; Kondo N; Wanifuchi-Endo Y; Fujita T; Asano T; Katagiri Y; Terada M; Kato A; Dong Y; Sugiura H; Okuda K; Kato H; Osaga S; Takahashi S; Toyama T
Breast Cancer Res Treat; 2021 May; 187(1):81-93. PubMed ID: 33782811
[TBL] [Abstract][Full Text] [Related]
2. Suppression of early hematogenous dissemination of human breast cancer cells to bone marrow by retinoic Acid-induced 2.
Werner S; Brors B; Eick J; Marques E; Pogenberg V; Parret A; Kemming D; Wood AW; Edgren H; Neubauer H; Streichert T; Riethdorf S; Bedi U; Baccelli I; Jücker M; Eils R; Fehm T; Trumpp A; Johnsen SA; Klefström J; Wilmanns M; Müller V; Pantel K; Wikman H
Cancer Discov; 2015 May; 5(5):506-19. PubMed ID: 25716347
[TBL] [Abstract][Full Text] [Related]
3. Retinoic acid-induced 2 (RAI2) is a novel tumor suppressor, and promoter region methylation of RAI2 is a poor prognostic marker in colorectal cancer.
Yan W; Wu K; Herman JG; Xu X; Yang Y; Dai G; Guo M
Clin Epigenetics; 2018; 10():69. PubMed ID: 29796120
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis of the expression and prognosis for RAI2: A promising biomarker in breast cancer.
Jiao Y; Li S; Gong J; Zheng K; Xie Y
Front Oncol; 2023; 13():1134149. PubMed ID: 37064084
[TBL] [Abstract][Full Text] [Related]
5. Expression Patterns and Corepressor Function of Retinoic Acid-induced 2 in Prostate Cancer.
Besler K; Węglarz A; Keller L; von Amsberg G; Bednarz-Knoll N; Offermann A; Stoupiec S; Eltze E; Semjonow A; Boettcher L; Schneegans S; Perner S; Hauch S; Todenhöfer T; Peine S; Pantel K; Wikman H; Werner S
Clin Chem; 2022 Jul; 68(7):973-983. PubMed ID: 35652463
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of TP53INP1 gene expression in estrogen receptor α-positive breast cancer patients.
Nishimoto M; Nishikawa S; Kondo N; Wanifuchi-Endo Y; Hato Y; Hisada T; Dong Y; Okuda K; Sugiura H; Kato H; Takahashi S; Toyama T
Jpn J Clin Oncol; 2019 Jun; 49(6):567-575. PubMed ID: 30855679
[TBL] [Abstract][Full Text] [Related]
7. Low TINAGL1 expression is a marker for poor prognosis in breast cancer.
Kato A; Kondo N; Wanifuchi-Endo Y; Fujita T; Asano T; Hisada T; Uemoto Y; Terada M; Kato H; Komura M; Okuda K; Takahashi S; Toyama T
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4771-4782. PubMed ID: 36229542
[TBL] [Abstract][Full Text] [Related]
8. RAI2 acts as a tumor suppressor with functional significance in gastric cancer.
Lou X; Deng W; Shuai L; Chen Y; Xu M; Xu J; Zhang Y; Wu Y; Cao Z
Aging (Albany NY); 2023 Oct; 15(21):11831-11844. PubMed ID: 37899172
[TBL] [Abstract][Full Text] [Related]
9. Retinoic Acid-Induced 2 (RAI2) Is a Novel Antagonist of Wnt/β-Catenin Signaling Pathway and Potential Biomarker of Chemosensitivity in Colorectal Cancer.
Zhang W; Kong L; Zhu H; Sun D; Han Q; Yan B; Cui Z; Zhang W; Zhang S; Kang X; Dai G; Qian N; Yan W
Front Oncol; 2022; 12():805290. PubMed ID: 35299743
[TBL] [Abstract][Full Text] [Related]
10. Plasma THBS1 as a predictive biomarker for poor prognosis and brain metastasis in patients with HER2-enriched breast cancer.
Li Y; Qin J; Chen G; Wu W; Sun X
Int J Clin Oncol; 2024 Apr; 29(4):427-441. PubMed ID: 38411882
[TBL] [Abstract][Full Text] [Related]
11. High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes.
Riaz M; Sieuwerts AM; Look MP; Timmermans MA; Smid M; Foekens JA; Martens JW
Breast Cancer Res; 2012 Sep; 14(5):R123. PubMed ID: 22967435
[TBL] [Abstract][Full Text] [Related]
12. High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level.
Xu C; Yamamoto-Ibusuki M; Yamamoto Y; Yamamoto S; Fujiwara S; Murakami K; Okumura Y; Yamaguchi L; Fujiki Y; Iwase H
Breast Cancer; 2014 Jul; 21(4):482-90. PubMed ID: 22968628
[TBL] [Abstract][Full Text] [Related]
13. Disseminated Tumor Cells in the Bone Marrow of Patients with Operable Primary Breast Cancer: Prognostic Impact in Immunophenotypic Subgroups and Clinical Implication for Bisphosphonate Treatment.
Stefanovic S; Diel I; Sinn P; Englert S; Hennigs A; Mayer C; Schott S; Wallwiener M; Blumenstein M; Golatta M; Heil J; Rom J; Sohn C; Schneeweiss A; Schuetz F; Domschke C
Ann Surg Oncol; 2016 Mar; 23(3):757-66. PubMed ID: 26467455
[TBL] [Abstract][Full Text] [Related]
14. JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer.
Reedijk M; Pinnaduwage D; Dickson BC; Mulligan AM; Zhang H; Bull SB; O'Malley FP; Egan SE; Andrulis IL
Breast Cancer Res Treat; 2008 Oct; 111(3):439-48. PubMed ID: 17990101
[TBL] [Abstract][Full Text] [Related]
15. Low expression levels of hepsin and TMPRSS3 are associated with poor breast cancer survival.
Pelkonen M; Luostari K; Tengström M; Ahonen H; Berdel B; Kataja V; Soini Y; Kosma VM; Mannermaa A
BMC Cancer; 2015 May; 15():431. PubMed ID: 26014348
[TBL] [Abstract][Full Text] [Related]
16. Higher expression levels of SOCS 1,3,4,7 are associated with earlier tumour stage and better clinical outcome in human breast cancer.
Sasi W; Jiang WG; Sharma A; Mokbel K
BMC Cancer; 2010 Apr; 10():178. PubMed ID: 20433750
[TBL] [Abstract][Full Text] [Related]
17.
Lang A; Goradia N; Wikman H; Werner S; Wilmanns M; Ohlenschläger O
Biomol NMR Assign; 2020 Oct; 14(2):271-275. PubMed ID: 32557393
[TBL] [Abstract][Full Text] [Related]
18. RAI2: Linking Retinoic Acid Signaling with Metastasis Suppression.
Esposito M; Kang Y
Cancer Discov; 2015 May; 5(5):466-8. PubMed ID: 25941336
[TBL] [Abstract][Full Text] [Related]
19. Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study.
Purdie CA; Quinlan P; Jordan LB; Ashfield A; Ogston S; Dewar JA; Thompson AM
Br J Cancer; 2014 Feb; 110(3):565-72. PubMed ID: 24300977
[TBL] [Abstract][Full Text] [Related]
20. Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer.
Magbanua MJM; Yau C; Wolf DM; Lee JS; Chattopadhyay A; Scott JH; Bowlby-Yoder E; Hwang ES; Alvarado M; Ewing CA; Delson AL; Van't Veer LJ; Esserman L; Park JW
Clin Cancer Res; 2019 Sep; 25(17):5388-5397. PubMed ID: 31142502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
